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Letter to the editor
The m.15043G > A MT-CYB variant is not a pathogenic mtDNA variant
Dear Editor,
We read with interest the article by Ghosh and colleagues describing
an adolescent male who presented with primary hypoparathyroidism
and extensive neurological involvement [2]; the authors conclude that
the mitochondrial DNA (mtDNA; NC_012920.1) variant,
m.15043G>A within MT-CYB is pathogenic and responsible for the
patient's neurological presentation.
We wish to briefly and unequivocally refute this conclusion; we
provide supporting evidence that the m.15043G > A mtDNA variant is
benign and does not underlie this patient's presentation.
1. The m.15043G > A variant is far too common to be pathogenic
ACMG guidelines are regarded as the benchmark for variant clas-
sification [5] and when applied to the synonymous m.15043G > A;
p.Gly99Gly variant demonstrate a neutral effect, primarily because of
its frequency. Stand-alone criteria BA1 can be applied given that it is
present in> 5% of the population; m.15043G > A is a single nu-
cleotide variant comprising the backbone of Haplogroup M and is
present in 23.6% of the MITOMAP dataset (a compendium of 51,192
mtDNA genome sequences) [4]. Moreover, we have observed the
m.15043G > A MT-CYB variant in approximately 10% of our own
patient cohort (> 2000 full mtDNA sequences) including a number of
patients with an alternative, established genetic diagnosis of mi-
tochondrial disease. In all instances, the m.15043G > A variant occurs
as a homoplasmic variant, consistent with its benign nature - the vast
majority of pathogenic mtDNA variations are heteroplasmic, bar a few
exceptions [3]. Segregation studies for pathogenic mtDNA variants
should be performed, where possible, using non-invasively sourced
maternal DNA samples (i.e. EDTA-blood, urinary sediment and buccal
epithelium) and mtDNA variant heteroplasmy levels correlated with
maternal clinical status and any relevant family history; unfortunately,
no segregation studies were performed nor is a family history docu-
mented.
2. There is no evidence of perturbed cytochrome b activity
The authors claim that “the homoplasmic mtDNA variant
m.15043G>A is pathogenic and perturbs cytochrome-b activity”. No
evidence is provided in support of this, and no muscle biopsy was
available in which to assess mitochondrial complex III activity.
3. Conclusion
While a number of the clinical features described in this case are
compatible with mitochondrial disease (sensorineural hearing loss, bi-
lateral ptosis and elevated blood and CSF lactates) others can be at-
tributed to chronic hypoparathyroidism – T1 hyperintense signal
abnormalities of basal ganglia, reversible cognitive impairment, muscle
weakness and choreiform limb movements. Nevertheless, assuming a
mitochondrial disease diagnosis is correct, analysis of the available data
underlies our opinion that the synonymous m.15043G > A variant is
not pathogenic and cannot therefore be the cause of the phenotype
described by the authors. This report highlights the importance of full
and thorough interpretation of patient genetic data to ensure that the
correct diagnosis is ascribed [1]. Moreover, it validates the clinical
utility of a diagnostic biopsy and the use of patient material for the
functional validation of genetic findings as the inadequate assessment
of pathogenicity has the potential to result in patient misdiagnosis and
mismanagement. Given the dual genetic control of mitochondrial
function and large number of possible Mendelian-mitochondrial ae-
tiologies, a gene agnostic whole exome or whole genome sequencing
approach would seem to be appropriate to ascertain a molecular di-
agnosis in the absence of a pathogenic mtDNA variant [6].
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